Gurbuz N, Kahraman N, Sonmez H, Mokhlis H, Koşar P, Ozpolat B. miRNA-193b-5p Suppresses Pancreatic Cancer Cell Proliferation, Invasion, Epithelial Mesenchymal Transition, and Tumor Growth by Inhibiting eEF2K. Anticancer Agents Med Chem. 2022;22:2607-2618 pubmed publisher

Naeem A, Harish V, Coste S, Parasido E, Choudhry M, Kromer L, et al. Regulation of Chemosensitivity in Human Medulloblastoma Cells by p53 and the PI3 Kinase Signaling Pathway. Mol Cancer Res. 2022;20:114-126 pubmed publisher

Zhou Z, Ambrogio C, Bera A, Li Q, Li X, Li L, et al. KRASQ61H preferentially signals through MAPK in a RAF dimer-dependent manner in non-small cell lung cancer. Cancer Res. 2020;: pubmed publisher

Nieuwenhuis B, Barber A, Evans R, Pearson C, Fuchs J, MacQueen A, et al. PI 3-kinase delta enhances axonal PIP3 to support axon regeneration in the adult CNS. EMBO Mol Med. 2020;:e11674 pubmed publisher

Citron F, Segatto I, Rampioni Vinciguerra G, Musco L, Russo F, Mungo G, et al. Downregulation of miR-223 expression is an early event during mammary transformation and confers resistance to CDK4/6 inhibitors in luminal breast cancer. Cancer Res. 2019;: pubmed publisher

Kowshik J, Nivetha R, Ranjani S, Venkatesan P, Selvamuthukumar S, Veeravarmal V, et al. Astaxanthin inhibits hallmarks of cancer by targeting the PI3K/NF-κΒ/STAT3 signalling axis in oral squamous cell carcinoma models. IUBMB Life. 2019;: pubmed publisher

Gao H, Xia Y, Zhang Y, Yang L, Kong L. Vielanin P enhances the cytotoxicity of doxorubicin via the inhibition of PI3K/Nrf2-stimulated MRP1 expression in MCF-7 and K562 DOX-resistant cell lines. Phytomedicine. 2019;58:152885 pubmed publisher

Trautmann M, Cyra M, Isfort I, Jeiler B, Krüger A, Grünewald I, et al. Phosphatidylinositol-3-kinase (PI3K)/Akt Signaling is Functionally Essential in Myxoid Liposarcoma. Mol Cancer Ther. 2019;18:834-844 pubmed publisher

Sophia J, Kowshik J, Dwivedi A, Bhutia S, Manavathi B, Mishra R, et al. Nimbolide, a neem limonoid inhibits cytoprotective autophagy to activate apoptosis via modulation of the PI3K/Akt/GSK-3β signalling pathway in oral cancer. Cell Death Dis. 2018;9:1087 pubmed publisher

Venot Q, Blanc T, Rabia S, Berteloot L, Ladraa S, Duong J, et al. Targeted therapy in patients with PIK3CA-related overgrowth syndrome. Nature. 2018;558:540-546 pubmed publisher

Zhao S, Cao Y, Liu S, Wang X, Bao R, Shu Y, et al. The E545K mutation of PIK3CA promotes gallbladder carcinoma progression through enhanced binding to EGFR. J Exp Clin Cancer Res. 2016;35:97 pubmed publisher

Sathe A, Guerth F, Cronauer M, Heck M, Thalgott M, Gschwend J, et al. Mutant PIK3CA controls DUSP1-dependent ERK 1/2 activity to confer response to AKT target therapy. Br J Cancer. 2014;111:2103-13 pubmed publisher

Samuels Y, Wang Z, Bardelli A, Silliman N, Ptak J, Szabo S, et al. High frequency of mutations of the PIK3CA gene in human cancers. Science. 2004;304:554 pubmed